Chicago—Six months of trastuzumab is noninferior to 12 months, according to results of the large, multicenter phase 3 PERSEPHONE study.
In addition to having similar efficacy, “six months compared with 12 months … reduces cardiotoxicity and other toxicities as well as costs both to patients and the health care system,” reported investigator Helena Margaret Earl, MBBS, PhD, a consultant medical oncologist at Cambridge University Hospitals, in England.
Initiated with or